27,351 Shares in Semler Scientific Inc. $SMLR Purchased by Nuveen LLC

Nuveen LLC purchased a new position in shares of Semler Scientific Inc. (NASDAQ:SMLR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 27,351 shares of the company’s stock, valued at approximately $990,000. Nuveen LLC owned about 0.28% of Semler Scientific as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SMLR. BNP Paribas Financial Markets purchased a new position in shares of Semler Scientific during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. boosted its holdings in Semler Scientific by 161.3% in the 1st quarter. SBI Securities Co. Ltd. now owns 959 shares of the company’s stock valued at $35,000 after purchasing an additional 592 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in Semler Scientific by 318.3% in the 4th quarter. NewEdge Advisors LLC now owns 732 shares of the company’s stock valued at $40,000 after purchasing an additional 557 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in Semler Scientific in the 4th quarter valued at approximately $163,000. Finally, Deutsche Bank AG boosted its holdings in Semler Scientific by 82.0% in the 1st quarter. Deutsche Bank AG now owns 4,893 shares of the company’s stock valued at $177,000 after purchasing an additional 2,204 shares in the last quarter. Hedge funds and other institutional investors own 49.37% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Maxim Group raised Semler Scientific to a “strong-buy” rating and set a $95.00 price objective on the stock in a report on Wednesday, July 9th. Wall Street Zen lowered Semler Scientific from a “buy” rating to a “sell” rating in a report on Thursday, May 22nd. Benchmark assumed coverage on Semler Scientific in a report on Tuesday, July 8th. They issued a “buy” rating and a $101.00 price objective on the stock. Finally, Cantor Fitzgerald lowered their price objective on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $81.75.

Semler Scientific Price Performance

Shares of NASDAQ:SMLR opened at $29.64 on Tuesday. The business’s 50 day simple moving average is $37.09 and its 200-day simple moving average is $36.98. The firm has a market capitalization of $438.97 million, a price-to-earnings ratio of 12.20 and a beta of 1.39. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58. Semler Scientific Inc. has a 12 month low of $21.77 and a 12 month high of $81.56.

Semler Scientific (NASDAQ:SMLR) last announced its quarterly earnings results on Monday, August 4th. The company reported $5.04 EPS for the quarter, topping the consensus estimate of ($0.27) by $5.31. The business had revenue of $8.22 million for the quarter, compared to analyst estimates of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.